← Back to list
Investigational Gene Expression, Biomarker, and Multianalyte Testing
Effective date
Sep 1, 2026
Identified
Jun 16, 2026
Summary
Effective September 1, 2026, the gene expression, biomarker and multianalyte tests named in this policy are considered investigational because current scientific evidence is not sufficient to establish their impact on health outcomes. Contracts exclude investigational services from coverage, and providers may bill members for services that are considered investigational.
Get alerts when payers change rules like this one
We check Regence BlueShield and other payers every day and email you when a change matches your specialty and state.
Get Regence BlueShield alertsPolicy Monitoring is free. No card required.
What to do
Action · 3 steps
01Already effective September 1, 2026: Services for the listed tests are considered investigational, and contracts exclude investigational services from coverage.
02Providers are encouraged to inform members before rendering these services that the members are likely to be financially responsible for the cost.
03Benefit determinations are based in all cases on the applicable contract language, which takes precedence over this policy.
Codes mentioned
8147981599
Original notice
Investigational Gene Expression, Biomarker, and Multianalyte Testing
beonbrand.getbynder.com · Always check the source before changing claims.
Related changes
See all Regence BlueShield changes →Investigational Gene Expression, Biomarker, and Multianalyte TestingMediumEffective Sep 1, 2026 · CodingEvaluating the Utility of Genetic PanelsMediumEffective Oct 1, 2026 · CodingLaboratory Tests for Organ Transplant RejectionMediumEffective Oct 1, 2026 · Laboratory & GeneticsMultianalyte Assays with Algorithmic Analysis for the Evaluation and Monitoring of Patients with Chronic Liver DiseaseMediumEffective Oct 1, 2026 · CodingBrowse every Regence BlueShield change in the policy list